Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 2 September 2024, 14:12 HKT/SGT
Share:
    

Source: Eisai
Eisai Announces Status Relating to Acquisition of Own Shares

Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. The status (progress report) of the acquisition is as described below.

1. Class of shares acquired: Ordinary shares of the Company
2. Total number of shares acquired: 1,598,800 shares
3. Aggregate amount of acquisition cost: JPY9,100,754,577
4. Acquisition period: From August 1 to August 31, 2024 (execution basis)
5. Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

For Reference

1. Resolution at a meeting of the Board of Directors held on May 15, 2024

(1) Class of shares to be acquired: Ordinary shares of the Company
(2) Total number of shares to be acquired: 6,500,000 shares (maximum)
(Ratio to total number of issued shares (excluding treasury shares): 2.3%)
(3) Total amount of acquisition cost: JPY30.0 billion (maximum)
(4) Period of acquisition: From May 16, 2024 to November 15, 2024
(5) Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

2. Accumulated number and price of own shares acquired in accordance with the above mentioned resolution at the meeting of Board of Directors (as of August 31, 2024)
(1) Total number of shares acquired: 4,037,300 shares
(2) Aggregate amount of acquisition cost: JPY24,933,137,242




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Jan 6, 2026 09:43 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Dec 11, 2025 18:41 HKT/SGT
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 9, 2025 17:51 HKT/SGT
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 4, 2025 17:36 HKT/SGT
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
Dec 3, 2025 17:19 HKT/SGT
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Dec 2, 2025 23:01 HKT/SGT
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Nov 28, 2025 22:00 HKT/SGT
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 26, 2025 18:42 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 17, 2025 21:08 HKT/SGT
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Oct 30, 2025 13:43 HKT/SGT
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: